GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptimmune Therapeutics PLC (STU:473A) » Definitions » Long-Term Debt

Adaptimmune Therapeutics (STU:473A) Long-Term Debt : €48.0 Mil (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Adaptimmune Therapeutics Long-Term Debt?

Adaptimmune Therapeutics's Long-Term Debt for the quarter that ended in Dec. 2024 was €48.0 Mil.

Adaptimmune Therapeutics's quarterly Long-Term Debt increased from Jun. 2024 (€23.2 Mil) to Sep. 2024 (€44.9 Mil) and increased from Sep. 2024 (€44.9 Mil) to Dec. 2024 (€48.0 Mil).

Adaptimmune Therapeutics's annual Long-Term Debt stayed the same from Dec. 2022 (€0.0 Mil) to Dec. 2023 (€0.0 Mil) but then increased from Dec. 2023 (€0.0 Mil) to Dec. 2024 (€48.0 Mil).

Adaptimmune Therapeutics Long-Term Debt Historical Data

The historical data trend for Adaptimmune Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptimmune Therapeutics Long-Term Debt Chart

Adaptimmune Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 47.98

Adaptimmune Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 23.18 44.93 47.98

Adaptimmune Therapeutics  (STU:473A) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Adaptimmune Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Adaptimmune Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptimmune Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptimmune Therapeutics PLC (STU:473A) » Definitions » Long-Term Debt
Comparable Companies
SER FBRX MGX STTK CTMX KRON ALGS GANX ANEB PDSB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
ADAP:USA 473A:Germany
Address
60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY
Website
https://www.adaptimmune.com
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Adaptimmune Therapeutics Headlines

No Headlines